BioCentury
ARTICLE | Clinical News

ETC-1002: Phase II data

January 21, 2013 8:00 AM UTC

Top-line data from a double-blind, U.S. Phase II trial in 60 Type II diabetics with hypercholesterolemia showed that once-daily oral ETC-1002 for 4 weeks reduced LDL-C, the primary endpoint, by up to ...